Topics & Collections
Search for a specific
disease or term
—  or  —
Learn more about ACP Smart Medicine


This content was provided by DynaMed ( For more information click here.
Last Updated: 1/25/2013  

Acute Coronary Syndromes

  • Ask patients about symptoms suggesting ACS, “typically” described as pressure, tightness or heaviness and radiates to the jaw, back or arm.

  • Obtain electrocardiogram immediately in all patients with suspected ACS.

  • Measure CK-MB and troponin T or I upon initial evaluation of patients with presumed ACS.

  • Consider using a diagnostic tool that combines history, physical exam, and laboratory data to aid in early risk stratification.

  • Use stress testing or consider coronary CT angiography in patients stratified as low-risk.

  • Give aspirin therapy promptly and continue in all patients with suspected ACS.

  • Proceed directly to coronary angiography in patients with STEMI who present to experienced centers or can be transferred to a referral center in order to perform a primary percutaneous intervention.

  • Administer a thrombolytic agent as an alternative to primary percutaneous interventions in suitable candidates with STEMI.

  • Give anticoagulant therapy with unfractionated heparin, low-molecular-weight heparin or bivalirudin, to moderate- and high-risk patients with ACS.

  • Administer clopidogrel or a newer P2Y12 receptor inhibitor in selected patients with ACS.

  • Consider administering glycoprotein IIb/IIIa antagonists in addition to aspirin and an anticoagulant in patients with high-risk NSTEMI, as adjunctive therapy in patients with STEMI undergoing primary percutaneous intervention, or as an alternative to P2Y12 receptor inhibitors.

  • Administer β-blockers early to patients with suspected ACS unless there are significant contraindications; give a nonselective β-blocker to patients with left ventricular dysfunction after an MI.

  • Administer nitroglycerin to with ACS with ongoing chest discomfort.

  • Administer an ACE inhibitor early in the course of ACS.

  • Prescribe high-potency HMG-CoA reductase inhibitors (statins) in patients with ACS and continue after hospitalization, with goal LDL<100 mg/dL.

  • Strongly advise all tobacco users who have had an acute coronary event to quit smoking.

  • Aim for glycemic control (glucose <180 mg/dL) in patients with diabetes.

DOI: 10.7326/d361
The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP.
Helene Glassberg, MD is a speaker for pharmaceutical companies. Rozy Desai, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sanjum S. Sethi, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Michael E. Farkouh, MD, MSc, FRCPC, FACC consults for Eli Lilly and AstraZeneca.
The following editors of ACP Smart Medicine have nothing to disclose: Deborah Korenstein, MD, FACP, Editor in Chief; Richard B. Lynn, MD, FACP, Editor; and Davoren Chick, MD, Editor.
Related Content
Annals of Internal Medicine